Furthermore, dipyridamole has been shown to (directly and probably indirectly through platelets) reduce aPL-induced NET formation from neutrophils and increased venous thrombosis in mice, suggesting a potential role for management of APS with venous thrombosis. This evidence concerns the gene FASLG and Venous thrombosis.